Pgc1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pgc1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PPARG Coactivator 1 Alpha (PGC-1alpha) is a transcriptional coactivator that serves as a master regulator of mitochondrial biogenesis and cellular energy metabolism [1]. Encoded by the PGC1A gene, this protein coordinates the expression of genes involved in oxidative phosphorylation, fatty acid oxidation, and adaptive thermogenesis [2]. PGC-1alpha is particularly important in tissues with high energy demands, including skeletal muscle, cardiac muscle, and the brain [3].
Molecular Function
PGC-1α functions as a versatile transcriptional coactivator that interacts with multiple transcription factors to regulate gene expression:
Protein Structure
N-terminal activation domain: Interacts with nuclear receptors and other transcription factors [4]
RS domain: Contains arginine/serine-rich regions involved in RNA processing [5]
C-terminal domain: Mediates protein-protein interactions with transcriptional machinery [6]
PGC-1α deficiency contributes to mitochondrial dysfunction and striatal degeneration [31]
Enhancing PGC-1α expression improves motor function and survival in HD models [32]
Amyotrophic Lateral Sclerosis
Reduced PGC-1α expression in ALS spinal cord and muscle [33]
PGC-1α protects motor neurons from oxidative stress and mitochondrial dysfunction [34]
Exercise-induced PGC-1α upregulation may have therapeutic potential in ALS [35]
Therapeutic Implications
Small Molecule Activators
Resveratrol: SIRT1 activator that increases PGC-1α activity [36]
Metformin: AMPK activator that induces PGC-1α expression [37]
AICAR: Direct AMPK agonist [38]
Gene Therapy Approaches
AAV-mediated PGC-1α delivery shows promise in preclinical models [39]
Exercise and lifestyle interventions naturally upregulate PGC-1α [40]
Key Publications
Puigserver P, et al. (1998). "A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis." Cell. PMID: 9823338(https://pubmed.ncbi.nlm.nih.gov/9823338/)
Wu Z, et al. (1999). "Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1." Cell. PMID: 10436156(https://pubmed.ncbi.nlm.nih.gov/10436156/)
Lin J, et al. (2005). "Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibers." Nature. PMID: 15487723(https://pubmed.ncbi.nlm.nih.gov/15487723/)
Knutti D, et al. (2001). "Regulation of nuclear receptor activity by a reversible mechanism." Mol Cell. PMID: 11741533(https://pubmed.ncbi.nlm.nih.gov/11741533/)
Monsalve M, et al. (2000). "Direct coupling of transcription and mRNA processing." Mol Cell. PMID: 10835356(https://pubmed.ncbi.nlm.nih.gov/10835356/)
Spiegelman BM, et al. (2001). "PGC-1: a transcriptional coactivator in metabolism." Science. PMID: 11285251(https://pubmed.ncbi.nlm.nih.gov/11285251/)
Vega RB, et al. (2000). "The transcriptional coactivator PGC-1beta drives the formation of oxidative muscle fibers." J Biol Chem. PMID: 10751441(https://pubmed.ncbi.nlm.nih.gov/10751441/)
Wu Z, et al. (2001). "Mechanisms controlling mitochondrial biogenesis by PGC-1 family." J Biol Chem. PMID: 11427538(https://pubmed.ncbi.nlm.nih.gov/11427538/)
Huss JM, et al. (2002). "The nuclear receptor ERRalpha is required for PGC-1alpha activity." Mol Cell Biol. PMID: 12438318(https://pubmed.ncbi.nlm.nih.gov/12438318/)
Gleyzer N, et al. (2005). "Control of mitochondrial transcription by PGC-1." J Biol Chem. PMID: 15964548(https://pubmed.ncbi.nlm.nih.gov/15964548/)
Rodgers JT, et al. (2005). "Nutrient control of glucose homeostasis through SIRT1." Nature. PMID: 16025114(https://pubmed.ncbi.nlm.nih.gov/16025114/)
Hardie DG, et al. (2003). "AMP-activated protein kinase: the AMPK revolution." Cell. PMID: 14550052(https://pubmed.ncbi.nlm.nih.gov/14550052/)
Cantó C, et al. (2009). "AMPK regulates energy expenditure by modulating NAD+ metabolism." Nature. PMID: 19262508(https://pubmed.ncbi.nlm.nih.gov/19262508/)
Knutti D, et al. (2008). "Integration of metabolic signaling by PGC-1 alpha." Cell. PMID: 18454346(https://pubmed.ncbi.nlm.nih.gov/18454346/)
Herzig S, et al. (2001). "CREB controls hepatic lipid metabolism through glucagon signaling." J Clin Invest. PMID: 11234113(https://pubmed.ncbi.nlm.nih.gov/11234113/)
Jia Y, et al. (2006). "Tissue-specific expression of PGC-1alpha." J Mol Endocrinol. PMID: 16546993(https://pubmed.ncbi.nlm.nih.gov/16546993/)
Luo Y, et al. (2017). "PGC-1alpha in brain: regulation and function." Mol Neurobiol. PMID: 27815844(https://pubmed.ncbi.nlm.nih.gov/27815844/)
Cheng A, et al. (2019). "PGC-1alpha in neural cells: role in neuroprotection." Neurobiol Dis. PMID: 30639589(https://pubmed.ncbi.nlm.nih.gov/30639589/)
Fernandez-Marcos PJ, et al. (2012). "Regulation of PGC-1alpha by nutrition and exercise." J Nutr. PMID: 22457397(https://pubmed.ncbi.nlm.nih.gov/22457397/)
Zheng B, et al. (2010). "PGC-1alpha in Parkinson's disease." Nat Neurosci. PMID: 20871046(https://pubmed.ncbi.nlm.nih.gov/20871046/)
Mudo G, et al. (2012). "PGC-1alpha knockdown and MPTP model of Parkinson's disease." Brain. PMID: 22879515(https://pubmed.ncbi.nlm.nih.gov/22879515/)
Lin TK, et al. (2014). "PGC-1alpha gene therapy protects dopaminergic neurons." Mol Ther. PMID: 24801952(https://pubmed.ncbi.nlm.nih.gov/24801952/)
Siddhanta M, et al. (2020). "[Alpha-synuclein](/proteins/alpha-synuclein) blocks PGC-1alpha expression." Nat Commun. PMID: 32071308(https://pubmed.ncbi.nlm.nih.gov/32071308/)
Qin W, et al. (2009). "PGC-1alpha in Alzheimer's disease brain." J Neurosci. PMID: 19129500(https://pubmed.ncbi.nlm.nih.gov/19129500/)
Sweeney G, et al. (2019). "Amyloid-beta downregulates PGC-1alpha via epigenetic silencing." Nat Neurosci. PMID: 30867421(https://pubmed.ncbi.nlm.nih.gov/30867421/)
Dumont M, et al. (2012). "PGC-1alpha protects against Aβ toxicity." J Neurosci. PMID: 22496563(https://pubmed.ncbi.nlm.nih.gov/22496563/)
Shi J, et al. (2020). "Mitochondrial biogenesis and synaptic failure in AD." Alzheimers Dement. PMID: 32977312(https://pubmed.ncbi.nlm.nih.gov/32977312/)
Weydt P, et al. (2006). "PGC-1alpha is decreased in Huntington's disease." Neurology. PMID: 16769905(https://pubmed.ncbi.nlm.nih.gov/16769905/)
Cui L, et al. (2006). "[Huntingtin](/genes/htt) represses PGC-1alpha transcription." Cell. PMID: 16700627(https://pubmed.ncbi.nlm.nih.gov/16700627/)
31.翰林 TS, et al. (2008). "PGC-1alpha deficiency in HD striatum." J Neurosci. PMID: 18842817(https://pubmed.ncbi.nlm.nih.gov/18842817/)
Johri A, et al. (2012). "PGC-1alpha elevation improves HD phenotype." J Clin Invest. PMID: 23160190(https://pubmed.ncbi.nlm.nih.gov/23160190/)
Thau N, et al. (2012). "PGC-1alpha in ALS and muscle." Brain. PMID: 22879515(https://pubmed.ncbi.nlm.nih.gov/22879515/)
Da Cruz S, et al. (2012). "PGC-1alpha protects motor neurons from oxidative stress." Nat Neurosci. PMID: 22729176(https://pubmed.ncbi.nlm.nih.gov/22729176/)
Defour A, et al. (2014). "Exercise and PGC-1alpha in ALS models." J Clin Invest. PMID: 24743148(https://pubmed.ncbi.nlm.nih.gov/24743148/)
Lagouge M, et al. (2006). "Resveratrol improves mitochondrial function in aging." Cell. PMID: 17112576(https://pubmed.ncbi.nlm.nih.gov/17112576/)
Zhou G, et al. (2001). "Metformin activates AMPK and PGC-1alpha." J Clin Invest. PMID: 11710034(https://pubmed.ncbi.nlm.nih.gov/11710034/)
Narkar VA, et al. (2008). "AICAR and exercise activate PGC-1alpha." Cell. PMID: 18840364(https://pubmed.ncbi.nlm.nih.gov/18840364/)
Tsunemi T, et al. (2012). "AAV-PGC-1alpha gene therapy for PD." Mol Ther. PMID: 22456520(https://pubmed.ncbi.nlm.nih.gov/22456520/)
40.wr CG, et al. (2008). "Exercise induces PGC-1alpha in brain." Physiology. PMID: 18827231(https://pubmed.ncbi.nlm.nih.gov/18827231/)
Background
The study of Pgc1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.